Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:55:56.401Z.
Calculation as of: 2026-10-06T16:55:56.401Z.
Quote observation: 2026-10-06T16:54:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dd458a7b7530169a13c79e175a6610edc18df904cb2af71895118b3708428af2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Boundless Bio, Inc.
Market Cap
$57.42M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Boundless Bio, Inc. (BOLD) | $57.42M | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $58.24M | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.78M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.79M | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.91M | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $59.74M | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.49M | N/A |
| Adicet Bio, Inc. (ACET)vs › | $60.48M | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.12M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
